Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States

Michael K WongUniversity of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA

, MD PhD,

Eric JonaschAnderson Cancer Center, Houston, TX, USA

, MD,

Sumanta K PalCity of Hope Comprehensive Cancer Center, Duarte, CA, USA

, MD,

James E SignorovitchAnalysis Group, Inc., Boston, 111 Huntington Ave, 10th Floor, MA, USA+1 617 425 8475; +1 617 425 8001; [email protected]

, PhD,

Peggy L LinAnalysis Group, Inc., Boston, 111 Huntington Ave, 10th Floor, MA, USA+1 617 425 8475; +1 617 425 8001; [email protected]

, PhD,

Xufang WangNovartis Pharmaceuticals Corp., East Hanover, NJ, USA

Zhimei LiuNovartis Pharmaceuticals Corp., East Hanover, NJ, USA

, PhD,

Ken CulverNovartis Pharmaceuticals Corp., East Hanover, NJ, USA

, MD,

Jeffrey A ScottCardinal Health, Grand Prairie, TX, USA

, MD,

Daniel J GeorgeGU Oncology, Duke Cancer Institute, Durham, NC, USA

Nicholas J VogelzangUS Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA

Your download is now in progress and you may close this window